CEO and Board Member, Cardea Bio
Biography
Michael is known for his motivational leadership style, the development of trusted relationships and his unique ability to engage talented people. He is dedicated to supporting ambitious goals and long-term strategies for the company, its employees and all of its highly valued partners. Michael has an extensive background in building and fostering the development of technology businesses, including but not limited to, the areas of: Digital Biology, Next-Gen Sequencing, Genomics, and Intercellular Communication. Prior to his role at Cardea Bio, he held leadership positions at CLC Bio, BGI, EXO Incubator, Nanosens, and BlueSEQ.
Genomic Profiling Showcase:
Cardea Bio
Cardea is a next-generation infrastructure company using graphene biosensors, biology and software to transform industries and Connect Life to the Internet.
Reinventing Biology: DNA Search & Biology-gated Transistors
Today, most information is only a few clicks away, but we don’t have access to one of the most fundamental types of information: Our biological information. Cardea’s graphene biosensor infrastructure can detect and convert biological signals to measurable digital information without need for amplification or optics.
Session Abstract – PMWC 2020 Silicon Valley
Track 6 - January 22 11.15 A.M.-1.15 P.M.,Track 7 - January 24 2.30 P.M.-3.45 P.M.
The PMWC 2020 Genomic Profiling Showcase will provide a 15 min speaking opportunity for selected companies working with the latest technologies in nucleic acid sequencing such as NGS, providing instrumentation for genomic sequencing, and offering direct to consumer services. These companies will share their innovative products and services to an audience of leading investors, potential clients and partners. The Genomic Profiling Showcase will exhibit the latest innovations in methods and instruments used for DNA/ RNA sequencing to ascertain the genomic and transcriptional profile of a person in order to understand why some people get certain diseases while others do not, or why people react in different ways to the same drug. This information is also being used to develop new ways to diagnose, treat, and prevent diseases, such as cancer.
